全文获取类型
收费全文 | 36255篇 |
免费 | 2266篇 |
国内免费 | 109篇 |
专业分类
耳鼻咽喉 | 321篇 |
儿科学 | 1169篇 |
妇产科学 | 1014篇 |
基础医学 | 4981篇 |
口腔科学 | 616篇 |
临床医学 | 5931篇 |
内科学 | 6593篇 |
皮肤病学 | 620篇 |
神经病学 | 3446篇 |
特种医学 | 606篇 |
外科学 | 3133篇 |
综合类 | 404篇 |
一般理论 | 55篇 |
预防医学 | 4534篇 |
眼科学 | 471篇 |
药学 | 2119篇 |
中国医学 | 68篇 |
肿瘤学 | 2549篇 |
出版年
2023年 | 198篇 |
2022年 | 382篇 |
2021年 | 778篇 |
2020年 | 459篇 |
2019年 | 780篇 |
2018年 | 898篇 |
2017年 | 621篇 |
2016年 | 651篇 |
2015年 | 834篇 |
2014年 | 1175篇 |
2013年 | 1783篇 |
2012年 | 2655篇 |
2011年 | 2810篇 |
2010年 | 1530篇 |
2009年 | 1291篇 |
2008年 | 2545篇 |
2007年 | 2549篇 |
2006年 | 2570篇 |
2005年 | 2387篇 |
2004年 | 2309篇 |
2003年 | 2188篇 |
2002年 | 2046篇 |
2001年 | 223篇 |
2000年 | 153篇 |
1999年 | 302篇 |
1998年 | 413篇 |
1997年 | 368篇 |
1996年 | 328篇 |
1995年 | 280篇 |
1994年 | 271篇 |
1993年 | 254篇 |
1992年 | 169篇 |
1991年 | 142篇 |
1990年 | 135篇 |
1989年 | 134篇 |
1988年 | 107篇 |
1987年 | 114篇 |
1986年 | 92篇 |
1985年 | 108篇 |
1984年 | 156篇 |
1983年 | 158篇 |
1982年 | 194篇 |
1981年 | 167篇 |
1980年 | 159篇 |
1979年 | 94篇 |
1978年 | 76篇 |
1977年 | 81篇 |
1976年 | 60篇 |
1975年 | 54篇 |
1974年 | 68篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Emeline Colomba Patricia Pautier Fanny Pommeret Alexandra Leary 《Expert review of anticancer therapy》2019,19(6):437-446
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.
Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献
3.
4.
Nurse perceptions of the Nursing Delirium Screening Scale in two palliative care inpatient units: a focus group study 下载免费PDF全文
5.
Background
The purpose of this study was to compare the outcomes of trauma patients who were injured in a motor vehicle crash and tested positive for alcohol upon hospital arrival versus those who tested negative.Methods
Study data came from the US National Trauma Data Bank (2007–2010). Any blood alcohol concentration (BAC) found at or above the legal limit (≥0.08?g/dL) was considered “alcohol positive”, and if no alcohol was identified through testing, the patient was considered “alcohol negative”. Patients’ demographics including age >?=?14, race, gender, drug test results, systolic blood pressure, heart rate, injury severity score (ISS), and Glasgow Coma Scale (GCS) were included in the study. Propensity score and exact pair matching were performed between the groups using baseline characteristics.Results
From a total of 88,794 patients, 30.9% tested positive and 69.1% tested negative for alcohol. There were significant differences found between the groups regarding age, gender, race, and GCS (all p?<?0.001) as well as a significantly higher in-hospital mortality rate (3.5% vs. 2.7%, p?<?0.001) and median time to patient expiration (4 vs. 3 days, p?<?0.001) in the alcohol negative group. After running both matching scenarios, there was no evidence of a significant difference seen in the rates of in-hospital mortality or the median time to patient expiration between the alcohol groups in either matched comparison.Conclusion
Patients who tested positive for alcohol following a traumatic motor vehicle crash showed no significant increase in in-hospital mortality or time to expiration when compared to propensity score and exact matched patients who tested negative for alcohol. 相似文献6.
Tuberculosis (TB) remains one of a major health problem worldwide. Tuberculosis vaccine research has made an extraordinary progress over the past few years. However, there is still no replacement for the Bacillus Calmette‐Guérin vaccine, the only TB vaccine licensed for human use. Therefore, the discovery and development of new TB vaccines remains a priority. This article discusses current strategies used to diversify TB vaccines and includes discussion of the status of efforts to improve protection against Mycobacterium tuberculosis (M tb) infection or TB disease by developing new and safe TB vaccines. This article also highlights the current research efforts in immune‐enhancing approaches to improve vaccination efficacy. The development of more effective TB vaccines might have significant impact on global TB control. 相似文献
7.
Rebecca Wright Caleb Ferguson Mustafa Bodrick Hanan Balkhy Debra Jackson Patricia M. Davidson 《Journal of clinical nursing》2020,29(13-14):2723-2729
8.
Jennifer C. Sasaki Ashley Allemang Steven M. Bryce Laura Custer Kerry L. Dearfield Yasmin Dietz Azeddine Elhajouji Patricia A. Escobar Albert J. Fornace Jr Roland Froetschl Sheila Galloway Ulrike Hemmann Giel Hendriks Heng-Hong Li Mirjam Luijten Gladys Ouedraogo Lauren Peel Stefan Pfuhler Daniel J. Roberts Véronique Thybaud Jan van Benthem Carole L. Yauk Maik Schuler 《Environmental and molecular mutagenesis》2020,61(1):114-134
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc. 相似文献
9.
10.